

Evidence-Based Neuropathy Treatments Without Medications: A Complete Guide

By Dr. Bradley Mouroux DC, CCSP

Introduction

Peripheral neuropathy is a widespread neurological condition marked by damage to peripheral nerves, leading to numbness, tingling, burning sensations, weakness and impaired balance (Joshua, 2022). U.S. population studies, peripheral neuropathy affects approximately 10.4 % of middle-aged adults (aged 40–69), rising to 26.8 % among those aged 70 and older and reaching 34.2 %–42.4 % in individuals aged 80 and above (Hicks et al., 2021). About 13.5 % of adults aged 40 and older are affected (Hicks et al., 2021). Globally, prevalence estimates are lower; about 2.4 % of the population experiences peripheral nerve disorders with rates of approximately 8 % in older age groups (Hämmi, 2022). When focusing on neuropathic pain, prevalence in the general population ranges from 7 % to 10 %, increasing to 20 %–30 % in people with diabetes (Baskozos et al., 2023). Disorders of the peripheral nervous system including polyneuropathy which account for approximately 10 % of all neurology visits globally each year (Elafros et al., 2022; Foundation for Peripheral Neuropathy, 2025). In the United States, direct annual healthcare costs for diabetic polyneuropathy are estimated at nearly \$11 billion (Foundation for Peripheral Neuropathy, 2025). Current drug-based treatments, such as gabapentin, pregabalin and duloxetine which target symptom relief rather than nerve repair which may cause dizziness, sedation, gastrointestinal upset and reduced adherence which shows the demand for safer alternatives. Increasing evidence supports non-pharmacological, integrative approaches such as photobiomodulation, extracorporeal shock wave therapy, electrical stimulation, vibration therapy, nutritional supplementation and chiropractic care which focus on nerve regeneration, improved circulation and functional recovery. Randomized controlled trials demonstrate measurable benefits; for example, infrared light therapy shows up to 66% improvement in pain and sensation scores, while shock wave therapy improves nerve conduction and reduces pain scores significantly over 12-week treatment courses. Electrical stimulation therapies, including transcutaneous electrical nerve stimulation (TENS) and pulsed electromagnetic field (PEMF) therapy, have demonstrated efficacy in reducing neuropathic pain. A meta-analysis of TENS interventions reported a standardized mean difference (SMD) of –1.58, indicating a significant reduction in pain intensity compared to sham treatments (Johnson et al., 2022). Studies on PEMF therapy have shown promising results with one study reporting a 41.6% decrease in visual analog scale (VAS) pain scores among cancer patients. Given the increasing prevalence of neuropathy, escalating healthcare costs and the limited efficacy of pharmacological treatments, both patients and clinicians are increasingly adopting integrative, evidence-based strategies. These approaches combine established therapies like TENS and PEMF with emerging modalities to enhance long-term outcomes and improve quality of life (Wang et al., 2024).

Understanding Peripheral Neuropathy: Causes and Symptoms

Peripheral neuropathy reflects failure of peripheral axons and Schwann cells from metabolic, vascular, toxic or immune causes. At the molecular level persistent hyperglycemia redirects glucose through the polyol pathway causing sorbitol accumulation, NADPH depletion and oxidative stress that disrupt axonal transport and mitochondrial function. Advanced glycation end products modify proteins and activate RAGE and NF- κ B signaling which sustains neuroinflammation and injures microvascular endothelium, reducing perfusion to nerves. Mitochondrial dysfunction and impaired mitophagy produce ATP deficit and excess reactive oxygen species which compromise distal axonal maintenance and slow axonal transport of mitochondria and neurotrophic factors. Inflammatory cytokines recruit macrophages and activate Schwann cells toward maladaptive phenotypes that promote demyelination and secondary axonal loss. Chemotherapy agents damage peripheral neurons through distinct molecular mechanisms. Taxanes stabilize microtubules and block axonal transport. Platinum compounds induce DNA adducts in dorsal root ganglia and disrupt mitochondrial bioenergetics. These insults alter ion channel expression including NaV and TRP families producing ectopic firing, allodynia and burning paraesthesia. Small fiber neuropathy selectively targets thin unmyelinated C fibers and small myelinated A δ fibers

and presents early as burning pain, thermal dysesthesia and autonomic dysfunction while large fiber involvement yields numbness, proprioceptive loss and gait instability. Injury related neuropathy from compression or trauma produces focal Wallerian degeneration. Idiopathic neuropathy likely reflects mixed metabolic, genetic and immune contributions that require targeted evaluation. Clinically early intervention is critical because progressive axonal loss predicts persistent disability. Detecting small fiber loss, correcting metabolic drivers, reducing toxic exposures and initiating neuroprotective or neuroregenerative therapies early offer the best chance to preserve fibers, restore conduction and reduce long term morbidity. (Laforgia et al., 2021; Li et al., 2024; Saleh & Sedik, 2024).

Infrared and Red Light Therapy for Neuropathy: Evidence and Benefits

Photobiomodulation, also called low level laser therapy or red and near-infrared light therapy, supports nerve recovery by acting on mitochondrial chromophores, notably cytochrome c oxidase, which increases ATP production, transiently modulates reactive oxygen species, releases nitric oxide and upregulates growth and angiogenic signals such as NGF and BDNF; these molecular effects reduce neuroinflammation, improve microvascular perfusion and restore axonal transport mechanisms repeatedly described in mechanistic reviews (Dompe et al., 2020). Clinical evidence from randomized trials and systematic reviews is consistent but heterogeneous. A sham-controlled trial in chemotherapy-induced peripheral neuropathy (70 patients) reported large, clinically meaningful reductions in modified Total Neuropathy Score with photobiomodulation versus sham at 4, 8 and 16 weeks (mTNS fell ~32% at 4 weeks and >50% at 8 weeks in the active arm). (Argenta et al., 2016) A 2023 randomized study in diabetic peripheral neuropathy (60 patients) using 630 nm and 810 nm, 15-minute sessions three times weekly for 12 sessions, improved monofilament detection and Michigan Neuropathy Screening Instrument scores without adverse events (Ebadi et al., 2023). Systematic reviews and focused meta-analyses summarize eight to twenty controlled studies showing improvement in neuropathic pain and nerve conduction velocity, while noting wide variability in wavelength, dose, irradiance and session number (Korada et al., 2022). Pragmatic treatment parameters used in trials range from 15 to 30 minutes per session, three times weekly, over 4 to 12 weeks, using visible red (around 630 nm) up to near-infrared (800–900 nm) devices. Reported safety is excellent in trials with negligible adverse effects (Ebadi et al., 2023). For patients the takeaways are precise: photobiomodulation offers a noninvasive option with plausible molecular rationale and level-II evidence of benefit, but effectiveness depends on correct wavelength, dose and clinical delivery. Home devices vary widely and have limited high-quality outcome data. Until standardized dosing and long-term trials are available clinicians should prefer clinic-grade, parameter-documented protocols or use home devices only under clinical guidance (De Oliveira Rosso et al., 2018).

Shockwave Therapy for Nerve Regeneration and Pain Relief

Extracorporeal shock wave therapy (ESWT) applies focused or radial acoustic pulses that mechanically stimulate tissue to trigger angiogenesis, growth factor release, stem cell recruitment and anti-inflammatory signaling, mechanisms that together foster axonal sprouting, remyelination and improved microvascular perfusion necessary for nerve repair (Guo et al., 2022) (Kou et al., 2024). Animal models show protection against diabetes-induced nerve degeneration, preservation of axons and recovery of motor and sensory function after ESWT (Chen et al., 2015). Clinical data are promising but heterogeneous. Systematic reviews and meta-analyses report consistent reductions in pain and functional gains across peripheral nerve and musculoskeletal indications with one review finding an average visual analogue scale reduction of about 1.49 points versus controls in randomized trials (De La Corte-Rodríguez et al., 2023). Recent neuropathy-focused reviews and a 2024 meta-analysis identified statistically significant improvements in pain, some

electrodiagnostic parameters and reductions in nerve cross-sectional area but effect sizes and study quality vary and follow-up durations are short (Yang et al., 2024). Typical clinical protocols reported in the literature use low to medium energy flux densities, commonly 0.08 to 0.28 mJ/mm² and 1,500 to 3,000 impulses per session, delivered in one to five sessions spaced days to weeks apart. The International Society for Medical Shockwave Treatment recommends tailoring energy and session number to device type and patient tolerance and notes transient local bruising, petechiae, or short-lived pain as the principal adverse events (International Society for Medical Shockwave Treatment., 2024). Key measurable outcomes observed in trials include clinically meaningful pain score reductions, improved monofilament or sensory testing in diabetic cohorts, shortened distal latency or increased sensory nerve action potential in some studies and decreased nerve cross-sectional area on ultrasound in others ("Effect of Extracorporeal Shockwaves on Diabetic Neuropathic Foot," 2020) (Jeong et al., 2023). At present ESWT for peripheral neuropathy should be regarded as a promising, mechanistically plausible therapy supported by moderate-quality evidence. Larger, parameter-standardized randomized trials with longer follow-up are required before ESWT can be considered established for routine neuropathy care (Yang et al., 2024) (International Society for Medical Shockwave Treatment, 2024).

Electrical Nerve Stimulation: TENS, PEMF and H-Wave Devices

Electrical nerve stimulation encompasses several distinct technologies that relieve neuropathic pain and may aid recovery by modulating neuronal excitability, increasing local blood flow and promoting neurotrophic signaling. TENS delivers pulsed current through skin electrodes to activate large diameter afferents and reduce pain via gate control and descending inhibition. High quality systematic reviews conclude TENS produces modest but real short term pain relief versus placebo with moderate certainty for immediate effects and no serious safety concerns (Johnson et al., 2022). Pulsed electromagnetic field therapy (PEMF) uses time-varying magnetic fields to alter membrane potentials, improve microvascular perfusion and potentially stimulate small fiber repair; recent pilot and randomized studies in diabetic symmetric peripheral neuropathy report improved skin perfusion pressure and pain scores, though samples remain small and protocols vary (Tassone et al., 2023). H-Wave is a proprietary waveform designed to produce non-fatiguing muscle contractions, enhance lymphatic and microvascular flow and reduce chronic pain. A focused review and several clinical reports show favorable pain and function outcomes, but many studies are small or industry supported and lack long follow up (Williamson et al., 2021) (Blum et al., 2008). Comparative data are limited. Direct comparisons in neuropathic or post-herpetic pain suggest TENS and PEMF can be similarly effective for short term pain reduction, while H-Wave aims to provide longer term functional gains through circulatory effects. One network of trials and secondary analyses reports a pooled mean pain intensity reduction of roughly -1.6 points on standard scales for electrical stimulation versus sham in mixed neuropathic conditions, but heterogeneity in devices, dose and outcome timing weakens certainty (Johnson et al., 2022). Clinically important points for practice are clear. TENS is inexpensive, widely available and suitable for home use with clinician instruction. PEMF and H-Wave generally require clinic delivery or validated prescription devices to ensure correct parameters. Adverse events are rare and usually limited to transient skin irritation or local discomfort. Because efficacy hinges on waveform, frequency, intensity, session length and placement, clinicians should document device parameters and use sham-controlled evidence where available when recommending a modality. Current evidence supports electrical stimulation as a safe adjunct that provides meaningful pain relief for many patients, but larger, parameter-standardized randomized trials with longer follow up are needed to define comparative effectiveness and optimal treatment regimens (Wolfe et al., 2024) (Vance et al., 2022).

Vibration Therapy and Sensory Stimulation

Vibration therapy and targeted sensory stimulation modify peripheral afferent input to improve circulation, proprioception and pain modulation through mechanotransduction, enhanced microvascular perfusion and reflexive increases in muscle spindle and cutaneous receptor activity. Whole-body vibration (WBV) and local plantar or focal vibration amplify sensory feedback, lower vibration perception thresholds and improve balance and gait by restoring sensory weighting in postural control circuits, while low-intensity vibration appears to support microvascular flow and neurotrophic signaling that can protect small fibers. Controlled trials and systematic reviews report consistent short-term gains in pain, balance and sensory thresholds in diabetic peripheral neuropathy with randomized studies showing pain reduction and improved neuropathy disability scores after multiweek WBV programs (Jamal et al., 2019) (Robinson et al., 2018). Local plantar vibration trials demonstrate improved protective sensation and postural stability and have reduced pain in small RCTs and feasibility studies, suggesting focal vibration may be particularly useful for distal, length-dependent neuropathies (Sabziparvar et al., 2022). Evidence for chemotherapy induced peripheral neuropathy is emerging but limited; pilot trials of low-intensity vibration indicate feasibility and possible symptom benefit yet larger randomized trials are needed to confirm durability (Krasnow et al., 2025) (Sohrabzadeh et al., 2021). Effect sizes vary by protocol. Several sham-controlled WBV trials reported clinically meaningful pain decreases within weeks and retained benefit beyond the day of treatment in some cohorts, but other preclinical and clinical studies show no structural regeneration on morphometry, exposing heterogeneity in dosing and outcomes (Kessler et al., 2020) (De Oliveira Marques et al., 2021). Practical guidance is straightforward. Patients with diabetic, age-related, or length-dependent neuropathy who have impaired balance, reduced foot sensation or chronic distal pain are most likely to benefit from supervised WBV or focal plantar vibration combined with balance and strength training. Contraindications include recent thromboembolism, unstable cardiovascular disease and acute fracture. Adverse effects are uncommon and usually transient, consisting of local discomfort, dizziness or mild musculoskeletal soreness. Clinicians should prioritize protocols validated in RCTs, document vibration frequency, amplitude, session duration and cumulative dose and couple vibration with exercise and metabolic optimization to maximize functional gains while awaiting larger, parameter-standardized trials.

Nutritional Supplements for Nerve Health

Nutritional supplementation plays a central role in strategies for protecting peripheral nerve function in conditions such as diabetic, idiopathic and chemotherapy-induced neuropathy (Liu., 2020). Benfotiamine, a lipid-soluble thiamine derivative, bypasses active transport limitations of thiamine and enhances transketolase activity, diverting glucose metabolites away from pathways that promote vascular and neural injury, including the hexosamine and advanced glycation end-product cascades (Brltramo., 2008). Mechanistic reviews confirm these molecular benefits but a 24-month randomized trial at 300 mg per day failed to show significant changes in nerve function or inflammation markers, suggesting its use may be most effective for symptom management in the short term. Short-term human studies, ranging from three to twelve weeks, indicate that high doses of benfotiamine up to 600 mg daily may improve symptom scores in diabetic polyneuropathy (Fraser., 2012). Clinical studies using 300 mg twice daily over several weeks have reported improvement in neuropathic symptoms without notable adverse effects. Omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit neuroprotective effects through anti-inflammatory signaling and support for myelin repair. A randomized, double-blind, placebo-controlled trial by Ghoreishi et al. (2012) assessed the efficacy of omega-3 fatty acids in reducing paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients. Participants receiving 640 mg of omega-3 fatty acids three times daily during chemotherapy and for one month after treatment experienced a significant reduction in neuropathy incidence. About 70% of the omega-3 group did not develop peripheral

neuropathy, compared to 40.7% in the placebo group, yielding an odds ratio of 0.3 (95% CI: 0.10–0.88, $p = 0.029$).

A systematic review and meta-analysis by Zhang et al. (2020) examined the effects of omega-3 polyunsaturated fatty acid supplementation on peripheral neuropathy. The pooled data indicated a reduced incidence of peripheral neuropathy with a relative risk of 0.58 (95% CI: 0.43–0.77), suggesting a protective effect of omega-3 supplementation against chemotherapy-induced peripheral neuropathy (Zhang et al., 2019). Trials in type 1 diabetes have demonstrated measurable improvement in corneal nerve fiber metrics, a validated biomarker of early small fiber neuropathy. These studies, along with FDA approval of daily intake up to 3 g of combined EPA and DHA, support the integration of omega-3 supplementation as a clinically meaningful preventive and restorative measure for neuropathy. Alpha-lipoic acid (ALA), a potent antioxidant and mitochondrial cofactor, has demonstrated consistent benefit in trials such as SYDNEY-2 and NATHAN 1, where daily dosing of 600 to 1,200 mg improved neuropathy symptom scores and nerve blood flow over months to years (Ziegler, 2023; Ziegler et al., 2006; Abdullah et al., 2024).

Though generally safe, higher doses may produce gastrointestinal discomfort. B-complex vitamins, including thiamine, pyridoxine, folate and cobalamin, are foundational for nerve metabolism and myelin synthesis and excessive pyridoxine intake above 50 mg daily is associated with sensory neuropathy and dosing should remain within evidence-based limits (Health Sciences Authority, 2023; Therapeutic Goods Administration, 2022). Magnesium is critical for nerve conduction and synaptic stability, is widely recommended to correct deficiency while neuropathy-specific data are limited. Diet and lifestyle interventions amplify the effects of supplementation; strict glycemic control, anti-inflammatory dietary patterns rich in omega-3 fatty acids and structured strength and balance training enhance microvascular health and neuronal resilience. Together, these interventions form a comprehensive approach where benfotiamine offers targeted glucose metabolism support, omega-3 fatty acids improve conduction and reduce inflammatory damage, ALA mitigates oxidative stress and B vitamins maintain metabolic integrity. Current evidence supports their inclusion in neuropathy treatment protocols, but long-term benefit depends on early diagnosis, critical metabolic management and combination with physical and rehabilitative therapies. Supplements should be selected and dosed under clinical guidance with close monitoring to ensure efficacy and safety (Health Sciences Authority, 2023).

Chiropractic Care for Improved Movement and Body Mechanics in Neuropathy

Chiropractic care focuses on optimizing joint mobility, spinal function, and overall biomechanics to address secondary effects of peripheral neuropathy, such as impaired balance, gait abnormalities, and compensatory pain. By restoring proper movement and alignment, chiropractic adjustments aim to enhance proprioceptive feedback, reduce mechanical stress on the body, and improve circulation, all of which create a better environment for nerve function and support a patient's ability to engage in rehabilitative exercise.

Restricted spinal or extremity joint motion can alter sensory input to the central nervous system, negatively affecting motor control and coordination. Manual therapies, including spinal manipulation and mobilization, work to normalize this input. Improved joint mechanics and reduced pain can lead to better movement patterns, increased stability, and a reduced risk of falls, a critical concern for neuropathy patients (Pollock et al., 2022).

While robust clinical trials specifically on chiropractic and neuropathy are limited, the rationale is supported by its documented effects on sensorimotor function. Case reports illustrate notable functional improvements where a chiropractic approach was part of a broader plan. In one example, a patient with severe foot burning and numbness underwent

a 12-week program combining chiropractic adjustments (focused on improving lumbar and lower extremity mobility), infrared therapy, electrical stimulation, and posture exercises. This multimodal approach resulted in dramatically reduced pain, improved walking, and decreased medication reliance (Chiropractic, 2025). Another case documented similar success by integrating spinal care with lifestyle coaching (Advantage Health Center, 2025).

Chiropractic care is inherently integrative, often working alongside physical therapy and rehabilitation. By addressing joint dysfunctions that may hinder exercise, chiropractic can help patients better tolerate and benefit from the sensory-motor training, strength work, and balance activities that are essential for stimulating nerves and improving functional outcomes (Comparative Efficacy of Chiropractic Adjustments in Peripheral Neuropathy Management, n.d.).

Vertebral Axial Decompression (VAX-D) Therapy in Neuropathy

Vertebral Axial Decompression (VAX-D) is a non-surgical spinal traction method employing computer-controlled, gradual pull on the lumbar spine to reduce intradiscal pressure. In one invasive physiological study, intradiscal pressure fell to below -100 mm Hg when tension was applied using a VAX-D table in an L4-L5 disc measurement scenario, indicating effective decompression of the nucleus pulposus (Ramos et al., 1994).

An outcomes study across 778 patients with chronic low back pain, often accompanied by radicular symptoms or degenerative disc conditions, found that 71 % of cases achieved a successful outcome is defined as pain reduction to a score of 0 or 1 on a 0–5 scale after at least ten VAX-D sessions (Gose et al., 1998). A similarly structured randomised controlled trial compared VAX-D versus TENS in patients with chronic low back pain and leg pain: 68.4 % of VAX-D patients met a pain reduction criterion (≥ 50 %) versus none in the TENS group ($p < .001$) (Naguszewski et al., 2001)

Physiological measures further support decompression. Using dermatomal somatosensory evoked potentials, researchers demonstrated lumbar nerve root decompression in seven patients with L5-S1 radiculopathy; 100 % reported at least 50 % symptom improvement, with average pain reduction of 77 % (Naguszewski et al., 2001).

However, critical data surfaces caution. A Mayo Clinic–reported case found that VAX-D triggered sudden enlargement of a lumbar disc protrusion after repeated sessions, escalating radicular pain and necessitating urgent microdiscectomy (McMillin & Sherry, 2002). Coverage policies by CMS and insurers reflect this uncertainty. Despite one RCT showing efficacy over TENS, they note methodological limitations, lack of blinding, limited generalizability and urge more rigorous testing (Aetna Clinical Policy Bulletins, 2025)

Combined Therapy Approaches: Creating a Personalized Neuropathy Plan

Multimodal therapy addresses neuropathy more effectively than single methods because it confronts multiple pathological processes simultaneously oxidative stress, impaired metabolism, inflammation, mechanical compression and altered nerve signaling. Evidence supports that combining antioxidant or lifestyle interventions with standard care improves outcomes. In one observational prospective study of diabetic neuropathy, combining glycemic control and lifestyle changes with antioxidant supplements increased response rates (decrease in Michigan Neuropathy Screening Instrument scores) from 34% to nearly 39% at one year (Rotaru et al., 2020).

Beyond supplements, clinical consensus and reviews emphasize that therapies combining pharmacologic and non-drug modalities outperform monotherapy. Reviews of neuropathic pain treatments note that combinations of gabapentin or pregabalin with other agents (e.g.,

COX-2 inhibitors) or the use of high-concentration topical agents with systemic treatments, yield better pain control and fewer side effects than each alone (Vorobeychik et al., 2011). While fewer trials combine non-drug devices, the rationale stands: modalities like photobiomodulation, ESWT, electrical stimulation, vibration therapy, vertebral axial decompression and nutritional support each affect different mechanisms and can be combined safely, increasing overall efficacy.

Case-based integration embodies this philosophy. In the chiropractic case described, spinal alignment, infrared light therapy, electrical nerve stimulation, supplements and lifestyle coaching coalesced to produce dramatic relief where standard treatments had failed (Chiropractic, 2025). Although anecdotal, such examples show how targeted combinations restore function, reduce symptoms and build patient trust.

To develop personalized plans, clinicians assess each patient's neuropathy subtype, symptom severity, comorbidities and response to initial interventions. They then layer therapies starting with core interventions like glycemic control or spinal decompression, followed by photobiomodulation, ESWT, stimulation devices and vetted supplements as needed. Case narratives help illustrate how that stacking approach can transform outcomes, offering both clinical credibility and empathic engagement.

Patient Success Stories: Real-World Recovery Journeys

William's Return to Mobility

William had suffered diabetic neuropathy for years and he has been tackling severe pain, tingling, numbness and loss of foot sensation forced him to rely on a cane and robbed him of restful nights. After receiving infrared light therapy combined with hyperbaric oxygen, he began noticing less pain within two weeks. By week five, he could move through his home without the cane and resumed stair climbing. A Semmes-Weinstein monofilament test showed sensation restored at nearly all tested points on his feet.

Link: [Whitaker Wellness Institute](#)

"I Regained Feeling in My Hands and Feet"

Judy, diagnosed with peripheral neuropathy, had been told relief would only come through pain medications. After laser therapy at a chiropractic and nerve-focused clinic, she regained sensation in both hands and feet and regained control over daily activities she'd lost to numbness.

Link: [midwestspineandnerve.com](#)

Chemotherapy-Induced Neuropathy Reversal

Scott struggled with neuropathy caused by chemotherapy and sought alternatives to exhaustion-inducing medications. Post-utilizing infrared laser therapy, his pain dropped dramatically while allowing him to regain function in his hands and feet and move with renewed comfort.

Link: [midwestspineandnerve.com](#)

"I'm Finally Able to Sleep"

Joan endured fifteen years of nightly neuropathic pain so severe it disrupted her sleep and daily life. After receiving infrared treatments three times weekly for over two months, she began sleeping soundly, her leg coloration normalized and pain vastly diminished.

Link: [midwestspineandnerve.com](#)

FAQs: Neuropathy Treatment Without Medications

Is laser therapy FDA-approved for neuropathy?

Low-level laser therapy (LLLT) and photobiomodulation are FDA-cleared for circulation and

pain, not specifically neuropathy reversal. RCTs show benefits in pain, sensation and nerve conduction and clinicians may use them “off-label” when evidence supports it.

How long does shockwave therapy take to work?

Extracorporeal shock wave therapy (ESWT) typically requires 1–5 weekly/biweekly sessions. Pain improves in 4–6 weeks with early sensory gains after three sessions; full effects can take 12–16 weeks.

Are electrical stimulation therapies effective?

TENS, PEMF and H-Wave stimulation reduce neuropathic pain. TENS provides short-term analgesia, PEMF enhances microcirculation and H-Wave supports lymphatic/vascular function. Correct protocols are crucial.

Can supplements replace medication?

Alpha-lipoic acid, omega-3s and benfotiamine improve symptoms and offer neuroprotection but do not replace drugs for severe or progressive neuropathy. ALA reduces symptoms by 24–32%; omega-3s may halve chemotherapy-induced neuropathy incidence.

Is chiropractic care safe for neuropathy?

Spinal adjustments and decompression are safe when performed by trained practitioners and may improve circulation, mobility and sensory function. Avoid in severe osteoporosis, spinal instability or advanced spondylosis.

Which therapy has the strongest evidence?

Alpha-lipoic acid and photobiomodulation have the most robust RCT support. ESWT, PEMF and vibration therapy show promising but smaller-scale evidence. Multimodal approaches yield the best long-term outcomes.

Can these therapies reverse neuropathy?

Some interventions, including omega-3s and exercise, can regenerate nerve fibers in early neuropathy. Advanced axonal loss is often irreversible, highlighting the importance of early treatment

Conclusion

Neuropathy management has advanced beyond symptomatic drug therapy with growing evidence for noninvasive interventions that target underlying mechanisms of nerve damage. Photobiomodulation, extracorporeal shockwave therapy, electrical stimulation, vibration-based sensory retraining, and carefully selected nutritional supplements demonstrate measurable improvements in pain, sensation and nerve conduction, especially in diabetic and chemotherapy-induced neuropathy. Chiropractic care and physical rehabilitation like vertebral axial decompression (when needed) further enhance circulation, improve sensorimotor function, and optimize body mechanics to support nerve health and functional capacity. Early treatment remains critical, as progressive axonal degeneration limits recovery potential. Patients benefit most when therapies are tailored to individual needs, monitored by clinicians and integrated with metabolic control and lifestyle interventions. This evidence-based, nonpharmacological approach emphasizes neuroprotection, regeneration and functional restoration, offering a realistic path toward improved quality of life and, in many cases, partial nerve recovery.

References

1. Abdullah, N., Tieppo Francio, V., Falowski, S., Ibrahim, Y., Malinowski, M., Budwany, R., ... & Pritzlaff, S. (2024). A Systematic Guideline by the ASPN Workgroup on the Evidence, Education and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET.

2. Advantage Health Center. (2025, April 7). Case study: Relief from peripheral neuropathy with chiropractic care. Advantage Health. <https://advantage-healthcenter.com/case-study-neuropathy-relief-eau-claire>
3. Argenta, P. A., Ballman, K. V., Geller, M. A., Carson, L. F., Ghebre, R., Mullany, S. A., Teoh, D. G., Winterhoff, B. J., Rivard, C. L., & Erickson, B. K. (2016). The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. *Gynecologic Oncology*, 144(1), 159–166. <https://doi.org/10.1016/j.ygyno.2016.11.013>
4. Baskozos, G., et al. (2023). Epidemiology of neuropathic pain: An analysis of prevalence. *Pain Reports*, 8(4), e1056. [Note: complete author list not specified; include as appropriate in final bibliography.]
5. Beltramo, E., Berrone, E., Tarallo, S., & Porta, M. (2008). Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. *Acta diabetologica*, 45(3), 131–141.
6. Blum, K., Chen, A. L., Chen, T. J., Prihoda, T. J., Schoolfield, J., DiNubile, N., Waite, R. L., Arcuri, V., Kerner, M., Braverman, E. R., Rhoades, P., & Tung, H. (2008). The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. *Advances in Therapy*, 25(7), 644–657. <https://doi.org/10.1007/s12325-008-0073-3>
7. Chen, Y., Chen, K., Yin, T., Huang, T., Yuen, C., Chung, S., Sung, P., Tong, M., Chen, C., Chang, H., Lin, K., Ko, S., & Yip, H. (2015, December 15). Extracorporeal shock wave therapy effectively prevented diabetic neuropathy. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4731656>
8. Chiropractic, A. (2025, April 7). Case study: Treating peripheral neuropathy with Chiropractic care. Advantage Chiropractic. <https://www.chiropractornewberlin.com/case-study-treating-neuropathy-with-chiropractic>
9. Comparative efficacy of chiropractic adjustments in peripheral neuropathy management. (n.d.). <https://www.backinactionbodyworks.com/blog/comparative-efficacy-of-chiropractic-adjustments-in-peripheral-neuropathy-management>
10. De La Corte-Rodríguez, H., Román-Belmonte, J. M., Rodríguez-Damiani, B. A., Vázquez-Sasot, A., & Rodríguez-Merchán, E. C. (2023). Extracorporeal shock wave therapy for the treatment of musculoskeletal pain: A Narrative review. *Healthcare*, 11(21), 2830. <https://doi.org/10.3390/healthcare11212830>
11. De Oliveira Marques, C., Espindula, I. A., Darko, E. K. K., Bonetti, L. V., Sonza, A., Partata, W. A., Faccioni-Heuser, M. C., & Malysz, T. (2021). Whole-body vibration therapy does not improve the peripheral nerve regeneration in experimental model. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8020024>
12. De Oliveira Rosso, M. P., Buchaim, D. V., Kawano, N., Furlanette, G., Pomini, K. T., & Buchaim, R. L. (2018). Photobiomodulation therapy (PBMT) in Peripheral Nerve Regeneration: A Systematic review. *Bioengineering*, 5(2), 44. <https://doi.org/10.3390/bioengineering5020044>
13. Dompe, C., Moncrieff, L., Matys, J., Grzech-Leśniak, K., Kocherova, I., Bryja, A., Bruska, M., Dominiak, M., Mozdziak, P., Skiba, T., Shibli, J., Volponi, A. A., Kempisty, B., & Dyszkiewicz-Konwińska, M. (2020). Photobiomodulation—Underlying mechanism and clinical applications. *Journal of Clinical Medicine*, 9(6), 1724. <https://doi.org/10.3390/jcm9061724>
14. Ebadi, S. A., Tabeie, F., Tavakoli, S., & Khalili, S. (2023). Effects of Photobiomodulation With Two Wavelengths of 630 and 810 nm on Diabetic Neuropathy. *Journal of Lasers in Medical Sciences*, 14, e22. <https://doi.org/10.34172/jlms.2023.22>

15. Effect of extracorporeal shockwaves on diabetic neuropathic foot. (2020). International Journal of Pharmaceutical Research, 12(04).
<https://doi.org/10.31838/ijpr/2020.sp2.554>
16. Elafros, M. A., Kvalsund, M. P., & Callaghan, B. C. (2022). The global burden of polyneuropathy—In need of an accurate assessment. JAMA Neurology, 79(6), 537–538. <https://doi.org/10.1001/jamaneurol.2022.0565>
17. Foundation for Peripheral Neuropathy. (2025). The global burden of polyneuropathy. Retrieved from Foundation for Peripheral Neuropathy website.
18. Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5), 1095-1097.
19. Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Jafarabadi, M. A., Montazeri, V., Keshavarz, S. A., & Darabi, M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer, 12(1).
<https://doi.org/10.1186/1471-2407-12-355>
20. Guo, J., Hai, H., & Ma, Y. (2022). Application of extracorporeal shock wave therapy in nervous system diseases: A review. Frontiers in Neurology, 13.
<https://doi.org/10.3389/fneur.2022.963849>
21. Hammi C, Yeung B. Neuropathy [Internet]. StatPearls - NCBI Bookshelf. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542220/>
22. Health Sciences Authority. (2023). High-dose vitamin B6 and risk of peripheral neuropathy. Retrieved from <https://www.hsa.gov.sg/announcements/safety-alert/high-dose-vitamin-b6-and-risk-of-peripheral-neuropathy>
23. Hicks, C. W., Wang, D., Windham, B. G., Matsushita, K., & Selvin, E. (2021). Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Scientific Reports, 11(1), Article 19159.
<https://doi.org/10.1038/s41598-021-98565-w>
24. International Society for Medical Shockwave Treatment. (2024, January 3). ISMST guidelines for extracorporeal shock wave therapy (ESWT).
<https://shockwavetherapy.org/wp-content/uploads/2024/01/ISMST-Guidelines-for-ESWT--en-20240103.pdf>
25. Jamal, A., Ahmad, I., Ahamed, N., Azharuddin, M., Alam, F., & Hussain, M. E. (2019). Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. Journal of Diabetes & Metabolic Disorders, 19(1), 61–69.
<https://doi.org/10.1007/s40200-019-00476-1>
26. Jeong, D., Lee, J. H., Lee, G. B., Shin, K. H., Hwang, J., Jang, S. Y., Yoo, J., & Jang, W. Y. (2023). Application of extracorporeal shockwave therapy to improve microcirculation in diabetic foot ulcers: A prospective study. Medicine, 102(11), e33310. <https://doi.org/10.1097/md.00000000000033310>
27. Johnson, M. I., et al. (2022). A secondary analysis of the Meta-TENS study to improve pain management. Nih. 58(6), 803. <https://doi.org/10.3390/jcm58060803>
28. Johnson, M. I., Paley, C. A., Jones, G., Mulvey, M. R., & Wittkopf, P. G. (2022). Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open, 12(2), e051073.
<https://doi.org/10.1136/bmjopen-2021-051073>
29. Johnson, M. I., Paley, C. A., Wittkopf, P. G., Mulvey, M. R., & Jones, G. (2022). Characterising the features of 381 clinical studies evaluating transcutaneous electrical nerve stimulation (TENS) for pain relief: A secondary analysis of the Meta-

TENS Study to improve future research. *Medicina*, 58(6), 803.
<https://doi.org/10.3390/medicina58060803>

30. Joshua, A. M., & Misri, Z. (2022). Peripheral nerve disorders. In *Physiotherapy for Adult Neurological Conditions* (pp. 621-729). Singapore: Springer Nature Singapore.
31. Kessler, N. J., Lockard, M. M., & Fischer, J. (2020). Whole body vibration improves symptoms of diabetic peripheral neuropathy. *Journal of Bodywork and Movement Therapies*, 24(2), 1–3. <https://doi.org/10.1016/j.jbmt.2020.01.004>
32. Korada, H. Y., Arora, E., Maiya, G. A., Rao, S., Hande, M., Shetty, S., Gundmi, S., Anche, P., & Amravadi, S. (2022). Effectiveness of photobiomodulation therapy on neuropathic pain, nerve conduction and plantar pressure distribution in diabetic peripheral neuropathy - a systematic review. *Current Diabetes Reviews*, 19(9). <https://doi.org/10.2174/1573399818666220429085256>
33. Kou, D., Chen, Q., Wang, Y., Xu, G., Lei, M., Tang, X., Ni, H., & Zhang, F. (2024). The application of extracorporeal shock wave therapy on stem cells therapy to treat various diseases. *Stem Cell Research & Therapy*, 15(1). <https://doi.org/10.1186/s13287-024-03888-w>
34. Krasnow, S. M., Rubin, C. T., Roeland, E. J., Horak, F. B., Stoyles, S. A., Dieckmann, N. F., Braun, K. N., & Winters-Stone, K. M. (2025). Low-Intensity vibration to reduce symptoms and improve physical functioning in cancer survivors with Chemotherapy-Induced peripheral neuropathy: a pilot randomized trial. *JCO Oncology Practice*. <https://doi.org/10.1200/op-24-00961>
35. Laforgia, M., Laface, C., Calabro, C., Ferraiuolo, S., Ungaro, V., Tricarico, D., ... & Ranieri, G. (2021). Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. *International journal of molecular sciences*, 22(4), 1980.
36. Li L, Li T, Qu X, Sun G, Fu Q, Han G. Stress/cell death pathways, neuroinflammation and neuropathic pain. *Immunological reviews*. 2024 Jan;321(1):33-51.
37. Liu, Y. W., Liu, C. T., & Su, Y. L. (2020). A narrative review of complementary nutritional supplements for chemotherapy-induced peripheral neuropathy. *Alternative Therapies in Health and Medicine*, 26(4), 43-49.
38. Robinson, C. C., Barreto, R. P. G., & Della M  a Plentz, R. (2018, September 1). Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6146195>
39. Rotaru, A., T  rtea, E. A., & Ianc  u, M. (2020). Classical therapies versus combined therapies in diabetic neuropathy. *PubMed*, 46(2), 123–128. <https://doi.org/10.12865/chsj.46.02.04>
40. Sabziparvar, M., Naghdi, S., Ansari, N. N., & Fateh, H. (2022). Implication of Local Plantar Vibration in Patients with Diabetic Neuropathy. *Iranian Journal of Public Health*. <https://doi.org/10.18502/ijph.v51i8.10284>
41. Saleh DO, Sedik AA. Novel drugs affecting diabetic peripheral neuropathy. *Iranian Journal of Basic Medical Sciences*. 2024;27(6):657.
42. Sohrabzadeh, E., Kalantari, K. K., Naimi, S. S., Daryabor, A., & Akbari, N. J. (2021). The immediate effect of a single whole-body vibration session on balance, skin sensation and pain in patients with type 2 diabetic neuropathy. *Journal of Diabetes & Metabolic Disorders*, 21(1), 43–49. <https://doi.org/10.1007/s40200-021-00933-w>
43. Tassone, E. E., Page, J. C., & Slepian, M. J. (2023). Assessing the effects of pulsed electromagnetic therapy on painful diabetic distal symmetric peripheral neuropathy: a Double-Blind randomized controlled trial. *Journal of Diabetes Science and Technology*. <https://doi.org/10.1177/19322968231190413>
44. Therapeutic Goods Administration. (2022). Health supplements containing vitamin B6 can cause peripheral neuropathy. Retrieved from <https://www.tga.gov.au/news/safety-alerts/health-supplements-containing-vitamin-b6-can-cause-peripheral-neuropathy>

45. Vance, C. G. T., Dailey, D. L., Chimenti, R. L., Van Gorp, B. J., Crofford, L. J., & Sluka, K. A. (2022). Using TENS for pain control: Update on the state of the evidence. *Medicina*, 58(10), 1332. <https://doi.org/10.3390/medicina58101332>
46. Vorobeychik, Y., Gordin, V., Mao, J., & Chen, L. (2011). Combination therapy for neuropathic pain. *CNS Drugs*, 25(12), 1023–1034. <https://doi.org/10.2165/11596280-000000000-00000>
47. Wang, Q., et al. (2024). The effects of pulsed electromagnetic field therapy on knee osteoarthritis: A randomized controlled trial. *Frontiers in Medicine*, 11, 1435277. <https://doi.org/10.3389/fmed.2024.1435277>
48. Williamson, T. K., Rodriguez, H. C., Gonzaba, A., Poddar, N., Norwood, S. M., & Gupta, A. (2021). H-Wave® Device stimulation: A critical review. *Journal of Personalized Medicine*, 11(11), 1134. <https://doi.org/10.3390/jpm11111134>
49. Wolfe, D., Rosenstein, B., & Fortin, M. (2024). The effect of EMS, IFC and TENS on patient-reported outcome measures for chronic low back pain: a systematic review and meta-analysis. *Frontiers in Pain Research*, 5. <https://doi.org/10.3389/fpain.2024.1346694>
50. Yang, L., Li, X., Li, S., Yang, J., & Meng, D. (2024). Effect of extracorporeal shock wave therapy on nerve conduction: a systematic review and meta-analysis. *Frontiers in Neurology*, 15. <https://doi.org/10.3389/fneur.2024.1493692>
51. Zhang, A. C., De Silva, M. E. H., MacIsaac, R. J., Roberts, L., Kamel, J., Craig, J. P., Busija, L., & Downie, L. E. (2019). Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. *Nutrition Reviews*, 78(4), 323–341. <https://doi.org/10.1093/nutrit/nuz054>
52. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Oral treatment with α -lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. *Diabetes care*. 2006 Nov 1;29(11):2365-70.
53. Ziegler, D. (2023). Pathogenetic treatments for diabetic peripheral neuropathy. *Diabetes Research and Clinical Practice*, 206, 110764.
54. Ramos, G., & Martin, W. (1994). Effects of vertebral axial decompression on intradiscal pressure. *Journal of Neurosurgery*, 81(3), 350–353.
55. Gose, E. E. et al. (1998). Vertebral axial decompression treatment for pain associated with herniated or degenerated discs or facet syndrome: An outcome study. *Neurological Research*, 20(4).
56. Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. *Neurol Res*. 2001 Oct;23(7):780-4. doi: 10.1179/016164101101199180. PMID: 11680522.
57. Naguszewski, W. K. et al. (2001). Dermatomal somatosensory evoked potential demonstration of nerve root decompression after VAX-D therapy. *Neurological Research*, 23(7).
58. McMillin, D. S., & Sherry, E. (2002). Sudden progression of lumbar disk protrusion during vertebral axial decompression traction therapy. *Mayo Clinic Proceedings*.
59. Aetna. (2025). Vertebral Axial Decompression [Clinical Policy Bulletin].